98%
921
2 minutes
20
Purpose: To evaluate the effectiveness of the Genomics ADvISER (www.genomicsadviser.com) decision aid (DA) for selection of secondary findings (SF), compared with genetic counseling alone.
Methods: A randomized controlled trial (RCT) was conducted to evaluate whether the Genomics ADvISER is superior to genetic counseling when hypothetically selecting SF. Participants were randomized to use the DA followed by discussion with a genetic counselor, or to genetic counseling alone. Surveys were administered at baseline and post-intervention. Primary outcome was decisional conflict. Secondary outcomes were knowledge, preparation for, and satisfaction with decision-making, anxiety, and length of counseling session.
Results: Participants (n = 133) were predominantly White/European (74%), female (90%), and ≥50 years old (60%). Decisional conflict (mean difference 0.05; P = 0.60), preparation for decision-making (0.17; P = 0.95), satisfaction with decision (-2.18; P = 0.06), anxiety (0.72; P = 0.56), and knowledge of sequencing limitations (0.14; P = 0.70) did not significantly differ between groups. However, intervention participants had significantly higher knowledge of SF (0.39; P < 0.001) and sequencing benefits (0.97; P = 0.01), and significantly shorter counseling time (24.40 minutes less; P < 0.001) CONCLUSIONS: The Genomics ADvISER did not decrease decisional conflict but reduced counseling time and improved knowledge. This decision aid could serve as an educational tool, reducing in-clinic time and potentially health care costs.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425118 | PMC |
http://dx.doi.org/10.1038/s41436-019-0702-z | DOI Listing |
Nat Rev Urol
September 2025
Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Low-grade non-muscle invasive bladder cancer is a specific category of bladder cancer with a favourable prognosis; however, its management presents several challenges. The risk of stage progression is very low, but approximately half of patients will experience recurrence within the first 5 years after diagnosis. This high propensity for recurrence, coupled with the threat of progression, mandates ongoing surveillance.
View Article and Find Full Text PDFEur J Public Health
September 2025
Danish Health Data Authority, Copenhagen, Denmark.
European Union (EU) Member States face challenges in using health data for secondary purposes, constrained by inconsistent digital health systems and limited cross-border sharing. One aim of the European Health Data Space (EHDS) is to facilitate secondary health data use through the HealthData@EU infrastructure and Health Data Access Bodies (HDABs). This article provides recommendations essential for HDAB implementation, informed by the HealthData@EU Pilot project.
View Article and Find Full Text PDFNat Rev Cardiol
September 2025
Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, Victoria, Australia.
A central paradigm in cardiac biology is the reactivation of the fetal gene programme in the adult heart in response to stress. This so-called 'fetal gene hypothesis' was first proposed almost 40 years ago following the observation that certain fetal contractile protein isoforms were re-expressed in hypertrophied ventricles in the rodent heart in response to haemodynamic overload. Consequently, this concept was broadly adopted, and activation of the fetal gene programme became synonymous in the literature with the cardiac stress response.
View Article and Find Full Text PDFNature
September 2025
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
The spatial resolution of omics analyses is fundamental to understanding tissue biology. The capacity to spatially profile DNA methylation, which is a canonical epigenetic mark extensively implicated in transcriptional regulation, is lacking. Here we introduce a method for whole-genome spatial co-profiling of DNA methylation and the transcriptome of the same tissue section at near single-cell resolution.
View Article and Find Full Text PDFbioRxiv
August 2025
The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
The SARS-CoV-2 pandemic provided a rare opportunity to study how human immune responses develop to a novel viral antigen delivered through different vaccine platforms. However, to date, no study has directly compared immune responses to all three FDA-approved COVID-19 vaccines at single-cell multi-omic resolution. We longitudinally profiled SARS-CoV-2-naïve adults (n=31) vaccinated with BNT162b2, mRNA-1273, or Ad26.
View Article and Find Full Text PDF